logo
When the time comes to die, what end-of-life care would doctors choose for themselves?

When the time comes to die, what end-of-life care would doctors choose for themselves?

The Guardian5 hours ago
The uncustomary quiet of a Sunday morning in the emergency department is broken by a universally relevant question.
'And if your heart were to suddenly stop beating, what would you like us to do?'
Standing outside, all I hear is a garbled response.
'That's right,' the voice reassures. 'You wouldn't want us jumping on your chest, would you?'
It seems to me that the doctor is having a one-way conversation, the kind I am about to have with my patient.
Following a bad fall months ago, my patient can't speak or move. I wonder what 'further functional decline' could possibly entail but her nursing home has sent her to emergency. She has pneumonia and a high sodium level not compatible with life. Yet, when I stand next to her and take her hand in mine, she smiles at me, displaying not an iota of distress.
The mild pneumonia might not take her life, but the untreated sodium level almost certainly will. What to do? Antibiotics and fluids or not?
'What would you like me to do?' I muse, hoping she will magically answer.
She smiles benignly. I am torn.
The doctor in the adjoining cubicle clearly doesn't want her patient undergoing CPR. I can't see how 'saving' my own patient from death would accord her better quality of life. Each doctor is making an irrevocable decision about a patient, its enormity compounded by the fact that both patients have limited capacity to participate in the conversation.
But what if the patient asked, 'Doctor, if you were in my situation, what would you do?'
Do doctors treat patients in the same way they would want to be treated at the end of life?
A new study sheds some light on this issue.
Researchers surveyed 1,157 doctors including GPs, palliative care physicians and other medical specialists working in diverse areas including Canada, Belgium and Italy, as well as the American states of Oregon, Wisconsin and Georgia, and the Australian states of Victoria and Queensland. These communities range from being socially progressive to religiously conservative to secular, with varying laws around assisted dying.
The study presented doctors with two end-of-life scenarios. In one, they have Alzheimer's disease. They don't recognise loved ones, refuse oral intake and are more withdrawn. In the second, they have advanced cancer not amenable to treatment. They are experiencing severe pain and agitation, have a prognosis of no more than two weeks, and are competent to make decisions. In each case, a palliative care provider and the option of inpatient hospice is available.
With preferences for end-of-life decisions including CPR, hydration, tube feeding, intensifying symptom alleviation, deep sedation until death and, where legal, assisted dying, doctors were asked to rate their own preferences from 'a very good option' to 'not at all a good option'.
Across all jurisdictions, physicians universally rejected the idea of CPR and mechanical ventilation (preferred by less than 1%), tube feeding (less than 4%) and intravenous hydration (about 20%). Of all physicians, over 90% considered it important to intensify symptom relief and just over half considered euthanasia a good or very good option. Notably, a third of physicians would consider using medications at their disposal to end their own life.
There are many interesting findings (regrettably, behind a paywall) but the bottom line is that when it comes to their own end-of-life care, doctors use their lived experience of medicine to choose differently, and arguably, more wisely.
This should give patients and doctors food for thought.
We are living in an era of medicine that often conflates more with better, an especially vexed issue at the end of life. In my own field of oncology, despite real concerns about time toxicity, overtreatment is believed to be a professionally sanctioned approach. No oncologist wants to be seen to 'do nothing' even if eschewing aggressive and harmful treatments in favour of quality of life is the opposite of doing nothing.
But the more I look around, I can't help thinking that oncologists are unfairly cast as the worst offenders when evidence of futile interventions is rife across healthcare.
How do grossly impaired patients end up being tube-fed? Why are frail, elderly people attached to ventilators? Why do unconscious patients receive antibiotics in their final days? Frankly, these events happen because patients or relatives demand them, and doctors find themselves unwilling or unable to say no.
The desire for a good death is as universal as the fact of dying. The researchers of this study should be commended.
If I were a patient, here is how I might use the study findings to help myself.
Instead of directly asking my treating doctor(s) what they would do in my situation (and risk a non-answer), I would inquire what factors they would consider in reaching a crucial medical decision. I would acknowledge that personal preferences vary and explain that their library of experiences might deepen my understanding of what to do.
As a physician, this study reminds me of the privilege of my role which gives me a sound basis for making highly consequential decisions.
The question is how to use my knowledge and experience to empower my patients without blurring the line between personal bias and professional guidance. I believe this is possible by listening carefully to patients' stated goals and including the views of their loved ones. These conversations need time and trust, which is what underpins good doctor-patient communication.
End-of-life decisions are a sensitive and complex situation, but one thing is evident to me.
If doctors clearly favour less aggressive measures at the end of life, their patients deserve to know why.
Ranjana Srivastava is an Australian oncologist, award-winning author and Fulbright scholar. Her latest book is called A Better Death
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SNP has left NHS fighting for its life as one in 10 operations are still being cancelled
SNP has left NHS fighting for its life as one in 10 operations are still being cancelled

Daily Mail​

time12 minutes ago

  • Daily Mail​

SNP has left NHS fighting for its life as one in 10 operations are still being cancelled

Scotland's NHS is 'dangerously flatlining' despite SNP promises to improve performance with almost one in 10 planned operations still being cancelled. Despite a pledge from John Swinney and his under-fire Health Secretary Neil Gray to 'renew' the NHS, new figures showed a decline in the number of planned operations in May compared to a year ago, while the number of them being cancelled has marginally increased. It led to concerns about the impact cancellations have on the physical and mental health of patients. Cases of patients being stuck in hospital because of bed-blocking were also similar in May compared to April, data from Public Health Scotland showed, sparking claims that the SNP Government has failed to deliver the improvements it has promised. Scottish Conservative public health spokesman Brian Whittle said: 'These figures confirm that our NHS is dangerously flatlining under Neil Gray and John Swinney's disastrous stewardship. 'Having an operation cancelled at the last minute takes a huge toll on the physical and mental wellbeing of patients. 'The reason the number of cancelled operations remains so stubbornly high is almost two decades of SNP mismanagement. From years of shoddy workforce planning to the knock-on effects of their failure to eliminate bed-blocking, Scots are paying the price for Nationalist incompetence.' The new Public Health Scotland figures showed that there were 25,067 operations planned to take place across the NHS in Scotland in May 2025, which was 311 lower than May 2024. The numbers had previously been steadily increasing since the coronavirus pandemic but 'began to plateau' from April 2024. In the period from June 2024 to May 2025 there was a 0.6 per cent increase compared to the previous 12 month period, but this was 14.6 per cent lower than the last full pre-Covid year in 2018/19. Public Health Scotland's report said: 'While a year-on-year increase is still being observed, the rate of growth has slowed.' In May 2025, 2,019, or 8.1 per cent, of all planned operations were cancelled, compared to 2,018, or 8 per cent, in May 2024. In three health boards, the rate of cancellations was well above one in ten, with 12.1 per cent in NHS Orkney, 10.5 per cent in NHS Dumfries and Galloway and 10.3 per cent in NHS Borders. Of those appointments cancelled, 437 did not go ahead because of hospital capacity or other non-clinical reasons. Scottish Labour health spokesman Jackie Baillie said: 'At a time when thousands of Scots are languishing on waiting lists waiting for treatment, it is a scandal that fewer operations are taking place. 'Far from tackling the crisis in our NHS, the SNP is fanning its flames.' Figures also showed bed-blocking - where patients are medically well enough to be discharged but are stuck in hospital because they do not have a care home place or an agreed care plan - remains a significant strain on the NHS. The number of these 'delayed discharge' cases was 1,840 in May 2025, compared to 1,868 in March 2025. An average of 1,852 beds were occupied per day because of delayed discharge in May, which is only a marginal decline on 1,864 in April. Dr Fiona Hunter, vice president of the Royal College of Emergency Medicine Scotland, said: 'Yet again, the evidence to address delayed discharges continues to mount. As I've said before, and I will say it again, the situation at our hospitals' 'backdoor', where we are unable to discharge people, is deeply concerning and distressing for both patients and the workforce. 'Patients when they are well enough to leave want to do just that - leave to continue their recovery. But often they can't because of a lack of social care.' She said 'seriously unwell people' in A&E are often left on trolleys waiting for a care bed, and added: 'So it is hard to celebrate slight improvements in extreme waiting times when every day my colleagues are struggling to admit vulnerable patients that need further care. 'Until available inpatient bed numbers increase the crisis in our EDs will continue.' Health Secretary Mr Gray said: 'Despite continued pressure on our health service it is encouraging to see an increase in the number of planned operations in the last year, compared to the previous twelve months. 'We are working closely with health boards across Scotland to maximise capacity and to ensure that any patients who have had their operations cancelled are seen as quickly as possible. 'Through an additional £200 million investment contained in the Budget to reduce waiting times and improve flow through hospital, we are creating extra appointments and procedures while making greater use of regional and national working.' On delayed discharge, he said: 'Alongside recent improvements in A&E waiting times, this latest data shows our efforts are working and our plan is delivering results. 'But we want to drive further improvements, which is why we are investing £200 million through our Budget to reduce waiting lists, expand capacity, and remove the barriers that keep patients in hospital longer than necessary - backed by a record £21 billion investment for Health and Social Care.'

What is toasted skin syndrome?
What is toasted skin syndrome?

Medical News Today

time14 minutes ago

  • Medical News Today

What is toasted skin syndrome?

Toasted skin syndrome (TSS) is a skin condition that occurs following chronic exposure to moderate heat or infrared radiation. Another name for this condition is 'erythema ab igne', which is Latin for 'redness from fire'.In TSS, repeated direct exposure to heat sources like heat pads, hot water bottles, or heated car seats may cause the skin to become pink and mottled. It may be harder to see on dark skin. Continued exposure to the heat source causes this mottling to darken and take on a reticulated or lace-like cases of TSS eventually resolve after a person stops exposing their skin to the heat source. However, people with severe TSS may experience permanent skin hyperpigmentation. Having TSS also increases the risk of certain types of skin article provides an overview of TSS and outlines the condition's symptoms, causes, and risk factors. We also describe how doctors diagnose and treat TSS, and consider the outlook for people with this skin syndrome (TSS) is a type of skin hyperpigmentation that develops following repeated exposure to moderate heat or infrared radiation. Potential sources of such include:heat pads or hot water bottlesheated car seatsspace heaterslaptops resting on thighsIn TSS, repeated direct contact with a heat source causes damage to the skin's elastic fibers and superficial blood vessels, resulting in hemosiderin deposition and overproduction of the pigment melanin. This process results in a type of mottled or lace-like deposition occurs when red blood cells leak and break down, and iron from those cells leaves a stain in the skin, causing brownish patches. It contributes to the mottled or net-like darkening seen in toasted skin syndrome. Removing the heat source can cause TSS to spontaneously resolve. However, repeated exposure to the heat source can lead to permanent hyperpigmentation. It may also lead to the progression of certain skin cancers, such as:Merkel cell carcinomabasal cell carcinomasquamous cell carcinomaSymptomsAs a 2021 case study explains, the skin lesions associated with TSS may not appear immediately after exposure to a heat source. Instead, they may take several weeks or months to to the American Osteopathic College of Dermatology (AOCD), the first sign of TSS is typically pink, mottled skin. With continued exposure to the heat source, the mottled areas may take on a reticulated or lace-like appearance, with the hyperpigmented areas becoming red, violet, or brown in and risk factorsToasted skin syndrome occurs when the skin comes into direct contact with a moderate-intensity heat source for a sustained period. This causes damage to the skin's elastic fibers and superficial blood vessels, releasing hemosiderin and melanin, which causes the affected area of skin to become hyperpigmented. Historically, TSS was more common among industry workers like bakers and metalworkers, who frequently had close exposure to heat sources. More recent risk factors for TSS include:resting a laptop on the thighsapplying heat pads or hot water bottles to the skinapplying a 'sauna belt' to help treat abdominal obesityusing a heated blanketusing a heated car seatusing a space heaterA 2021 review adds that TSS is more common among women compared to men, and is also more common among people with chronic diagnosing TSS, doctors will consider a person's symptoms alongside any history of heat exposure. In some cases, doctors may take a small sample of the affected skin and examine it under a microscope to look for characteristic signs of TSS. This type of test is called a biopsy, and it can help to rule out other conditions with similar symptoms. According to a 2018 case study, these conditions may include:livedo reticularislivedo racemosacutis marmoratacutis marmorata telangiectatica congenitaTreatmentA 2018 case study notes that TSS typically resolves after a person stops exposing their skin to the heat source. However, since TSS increases the risk of certain skin cancers, individuals who have TSS with skin ulceration or non-healing wounds should undergo a skin biopsy to rule out skin to the AOCD, more advanced cases of TSS may persist for years, and some may even be permanent. Some individuals with permanent hyperpigmentation may have concerns about the appearance of their skin. Treatments that may help to improve the appearance of TSS hyperpigmentation include:the topical treatment '5-fluorouracil'the topical retinoid 'tretinoin'laser therapyOutlookAccording to a 2021 review, TSS usually resolves within weeks or months of removing the heat source, although the rash may become permanent. The review adds that in some cases, TSS may develop into a type of skin cancer, such as:cutaneous squamous cell carcinomaMerkel cell carcinomaheat-induced basal cell carcinomaAnyone who has received a diagnosis of TSS and has continued concerns about their skin can talk to a doctor or dermatologist for further information and skin syndrome (TSS) or 'erythema ab igne' is a type of skin hyperpigmentation that occurs when the skin persistently comes into direct contact with a moderate-intensity heat source, or infrared radiation. In TSS, heat causes the skin's elastic fibers and superficial blood vessels to break down, releasing hemosiderin and melanin. This results in patchy hyperpigmentation that may darken over time and take on a lace-like or mottled diagnose TSS according to a person's symptoms and history of heat exposure. In some cases, doctors may take a skin biopsy to rule out other main treatment for TSS is removal of the heat source, and this method resolves most TSS cases within months. However, severe cases can cause permanent hyperpigmentation, and also increase the risk of certain skin cancers. Anyone who has concerns about this can talk to a doctor or dermatologist for further advice.

AstraZeneca boss ‘wants to shift stock market listing to US'
AstraZeneca boss ‘wants to shift stock market listing to US'

The Guardian

time25 minutes ago

  • The Guardian

AstraZeneca boss ‘wants to shift stock market listing to US'

AstraZeneca's chief executive, Pascal Soriot, has reportedly said that he would like to shift the company's stock market listing from the UK to the US. The boss of Britain's most valuable listed company has spoken privately about a preference to move the listing to New York, the Times reported. It added that he had also considered moving the company's domicile. The FTSE 100 company's share price rose by 2.8% on Tuesday, with most of the increase happening after the story was published. A shift in AstraZeneca's listing would deal a major blow to the London Stock Exchange, which has already had to deal with a series of departures by companies seeking higher valuations. Among those who have left the FTSE 100 in recent years are equipment rental company Ashtead, Paddy Power bookmaker owner Flutter Entertainment, building materials supplier CRH and packaging company Smurfit Westrock. A shift by AstraZeneca would almost certainly face opposition by the UK government, although it would not have the power to formally block a move. Labour made life sciences one of its key growth sectors in its industrial strategy published last month. A spokesperson for AstraZeneca declined to comment. The government remains stuck in negotiations with the drug industry, including AstraZeneca, over rebates that pharmaceutical companies must pay on sales of new medicines to the NHS, under a voluntary agreement. Soriot has publicly expressed his frustration over the rejection of AstraZeneca'sbreast cancer drug Enhertu for use in the NHS on cost grounds. Earlier this year, the company, headquartered in Cambridge, caused consternation in government by pulling out of a £450m project to produce vaccines in Speke, Liverpool, while saying that the business case did not make sense without more financial support from government. Soriot has overseen the market value of AstraZeneca more than tripling since he took over in October 2012. The company has overtaken oil company Shell – also seen as a contender for a move to the US – and HSBC, a bank, with a market value of £157bn. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion The US is the world's biggest pharmaceutical market, with by far the highest spending per person on medicines despite having a lower life expectancy than several other countries. UK executives have long complained that their companies are undervalued compared with American counterparts. Soriot has emphasised the company's ambitions to grow in the US. In November, he told investors that 'we want to see even more growth in the US over the next few years as part of our 2030 ambition,' according to a transcript from data company Alphasense. The 'US is, of course, a very important market and that supports innovation, and we will continue to invest to grow fast in this part of the world', Soriot said. The chief executive's pay has increased in line with AstraZeneca's market value. He has been the highest-paid chief executive on the FTSE 100 for two years running, receiving £16.85m for 2023, up from £15.3m in 2022.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store